| Simulect (basiliximab) / Novartis |
NCT00594308: In-Vivo Activated T-Cell Depletion to Prevent GVHD |
|
|
| Terminated | N/A | 10 | US | Cyclophosphamide, Fludarabine, Cyclosporine, Mycophenolate mofetil, Basiliximab | Indiana University | Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplasia, Lymphoma, Non-Hodgkin's, Mantle-Cell Lymphoma, Hodgkin's Disease, Multiple Myeloma, Myelofibrosis | 10/08 | | | |
NCT00563108: Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation |
|
|
| Unknown status | N/A | 60 | RoW | Basiliximab, Placebo | Hospital Authority, Hong Kong, Novartis Pharmaceuticals, The Hong Kong Blood Cancer Foundation | Graft vs Host Disease, Hematopoietic Stem Cell Transplantation | | 12/08 | | |
NCT00842699: Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab |
|
|
| Completed | N/A | 40 | US | | Brigham and Women's Hospital, Genzyme, a Sanofi Company | Renal Transplantation | 09/10 | 03/11 | | |
NCT01387659: Evaluate Tolerability of Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations |
|
|
| Terminated | N/A | 2 | US | Gastric emptying test, Gastric motility | The University of Texas Medical Branch, Galveston, Novartis Pharmaceuticals | Diabetes, Immunosuppression | 10/12 | 10/12 | | |
ChiCTR-OCH-12002890: Treatment of Severe Steroid-refractory Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplantation |
|
|
| Completed | N/A | 60 | | Treatment with Etanercept and Basiliximab ;Basiliximab ;Etanercept | the First Affiliated Hospital of Zhejiang University School of Medicine; None, Self-funding | hematologic malignacy | | | | |
NCT01049633: B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure |
|
|
| No Longer Available | N/A | | US | Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab, Tacrolimus, Antibacterial, Antifungal, and Antiviral Prophylaxis, Trimethoprim/sulfamethoxazole, Septra SS, Clotrimazole, Mycelex Troche, Valganciclovir, Valcyte, Heparin, Anticoagulation and Hematological Agent, Enoxaparin, Lovenox; Anticoagulation and Hematological Agent, Pentoxifylline, Aspirin, ASA | National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes Mellitus | | | | |
NCT02459977: The Usefulness of Tacrolimus Without Basiliximab in Well Matched Living Renal Transplantation in Korea |
|
|
| Unknown status | N/A | 40 | RoW | Basiliximab, No basiliximab, Kidney transplantation | Asan Medical Center | Kidney Transplantation | 06/15 | | | |
THYMO B, NCT02894606: Influence of Thymoglobuline on Phenotypic and Functional Profiles of B Lymphocytes in Renal Transplant Recipients |
|
|
| Unknown status | N/A | 40 | Europe | Thymoglobulin Induction, Basiliximab Induction | University Hospital, Brest | Renal Transplant | 02/18 | 02/18 | | |
NCT02409147: Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center |
|
|
| Withdrawn | N/A | 0 | NA | Uterine Transplant, Thymoglobulin, Basiliximab, Prograf, Cellcept, Prednisone, Bactrim, Valcyte, Aspirin, Nystatin | University of Nebraska | Uterus Transplant | 07/18 | 07/18 | | |
NCT01265537: A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf |
|
|
| Completed | N/A | 30 | Canada | Tacrolimus, Advagraf | University of British Columbia, Astellas Pharma Canada, Inc. | Acute Graft Rejection, Diabetes | 02/19 | 10/19 | | |
TReg Kidney, NCT02730715: Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients |
|
|
| Terminated | N/A | 30 | US | Basiliximab, Simulect, Thymoglobulin, Anti-thymocyte globulin | University of Pennsylvania | KIDNEY TRANSPLANTATION | 04/20 | 04/20 | | |
ChiCTR1900028311: The study of efficacy and safety of basiliximab in the treatment of steroid-resistant graft-versus-host disease after allogeneic hematopoietic stem cell transplantation |
|
|
| Recruiting | N/A | 288 | | None | Peking University People's Hospital; Peking University People's Hospital, the Foundation for Innovative Research Groups of the National Natural Science Foundation of China | Hematological disease | | | | |
| Completed | N/A | 958 | RoW | Basiliximab Injection, Simulect, rabbit ATG, Thymoglobuline | Gang Chen, Zhejiang University, First Affiliated Hospital, Sun Yat-Sen University, The First Affiliated Hospital of Zhengzhou University, Changhai Hospital | Kidney Transplant Rejection, Pediatric Kidney Disease | 07/22 | 09/23 | | |
| Not yet recruiting | N/A | 75 | Europe | RATG, Thymoglobulin, Basiliximab, Simulect | Mario Negri Institute for Pharmacological Research | Kidney Replacement | 09/25 | 09/25 | | |
